# Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

> **NCT03936426** · PHASE1,PHASE2 · COMPLETED · sponsor: **Clarity Pharmaceuticals Ltd** · enrollment: 5 (actual)

## Conditions studied

- Meningioma

## Interventions

- **DRUG:** Cu-64 SARTATE and Cu-67 SARTATE

## Key facts

- **NCT ID:** NCT03936426
- **Lead sponsor:** Clarity Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-09
- **Primary completion:** 2019-09-19
- **Final completion:** 2019-09-19
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03936426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03936426, "Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03936426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*